Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011220 | 0.85 | MAOB (0.57) | MAOBMPOIDO1MRGPRX4 | |
| SCHEMBL4014567 | 0.80 | MPO (0.48) | MAOBMPOIDO1 | |
| SCHEMBL219145 | 0.76 | ALDH1A1 (0.44) | KMT2A | |
| SCHEMBL4016083 | 0.73 | MAOB (0.54) | MAOBMPOIDO1 | |
| SCHEMBL18640100 | 0.71 | MAOB (0.56) | MAOB | |
| SCHEMBL4012289 | 0.71 | MPO (0.53) | MAOBMPOIDO1 | |
| SCHEMBL11183436 | 0.70 | MAOB (0.67) | MAOBIDO1 | |
| SCHEMBL28241500 | 0.69 | MAOB (0.49) | MAOBMPOIDO1KMT2AMRGPRX4 | |
| SCHEMBL4334933 | 0.69 | MAOB (0.65) | MAOBIDO1 | |
| SCHEMBL5846176 | 0.69 | MAOB (0.65) | MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MAOB 695/4885MPO 733/4885IDO1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.